Penumbra price target raised to $312 from $301 at BTIG

BTIG analyst Ryan Zimmerman raised the firm’s price target on Penumbra to $312 from $301 and keeps a Buy rating on the shares after its Q1 earnings beat and guidance raise. The source of upside was Neurovascular despite Peripheral Vascular being in the "early launch phases of Flash and Bolt", the analyst tells investors in a research note, adding that these products should deliver against bullish expectations.